<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">lvrach</journal-id><journal-title-group><journal-title xml:lang="ru">Лечащий Врач</journal-title><trans-title-group xml:lang="en"><trans-title>Lechaschi Vrach</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1560-5175</issn><issn pub-type="epub">2687-1181</issn><publisher><publisher-name></publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.51793/OS.2025.28.4.011</article-id><article-id custom-type="elpub" pub-id-type="custom">lvrach-1391</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>АКТУАЛЬНАЯ ТЕМА</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>TOPICAL THEME</subject></subj-group></article-categories><title-group><article-title>Нестероидные противовоспалительные средства в периоперационном периоде хирургии катаракты</article-title><trans-title-group xml:lang="en"><trans-title>Nonsteroidal anti-inflammatory drugs in perioperative period of cataract surgery</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6949-1002</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Левашов</surname><given-names>И. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Levashov</surname><given-names>I. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Левашов Илья Андреевич - к.м.н., врач-офтальмолог хирургического отделения.</p><p>117593, Москва, Севастопольский проспект, 66</p></bio><bio xml:lang="en"><p>Ilia A. Levashov - Cand. of Sci. (Med.), ophthalmologist of the Surgical Department, Multidisciplinary Medical Center of the Central Bank Of the Russian Federation.</p><p>66 Sevastopolsky Prospekt, Moscow, 117593</p></bio><email xlink:type="simple">levashov.ilia@osp.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0004-9821-9533</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Городецкий</surname><given-names>Д. Б.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorodetskiy</surname><given-names>D. B.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Городецкий Дмитрий Борисович - студент Института клинической медицины.</p><p>117997, Москва, ул. Островитянова, 1</p></bio><bio xml:lang="en"><p>Dmitriy B. Gorodetskiy - student of the Institute of Clinical Medicine, Federal State Autonomous Educational Institution of Higher Education N.I. Pirogov Russian National Research Medical University of the Ministry of Health of the Russian Federation.</p><p>1 Ostrovityanova str., Moscow, 117997</p></bio><email xlink:type="simple">dbgdoc@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Многопрофильный медицинский центр Центрального банка Российской Федерации</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Multidisciplinary Medical Center of the Central Bank of the Russian Federation</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Российский национальный исследовательский медицинский университет имени Н.И. Пирогова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>N.I. Pirogov Russian National Research Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>09</day><month>04</month><year>2025</year></pub-date><volume>0</volume><issue>4</issue><fpage>76</fpage><lpage>79</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Левашов И.А., Городецкий Д.Б., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Левашов И.А., Городецкий Д.Б.</copyright-holder><copyright-holder xml:lang="en">Levashov I.A., Gorodetskiy D.B.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.lvrach.ru/jour/article/view/1391">https://journal.lvrach.ru/jour/article/view/1391</self-uri><abstract><sec><title>Введение</title><p>Введение. Медикаментозное сопровождение хирургии катаракты является ее неотъемлемой частью. Стандартная схема локальной терапии включает в себя антибиотик, глюкокортикостероид и нестероидный противовоспалительный препарат. Каждый из множества нестероидных противовоспалительных препаратов обладает уникальными фармакологическими особенностями, что обусловливает актуальность информации о выборе препарата из этой группы в медикаментозном сопровождении хирургии катаракты.</p></sec><sec><title>Цель работы</title><p>Цель работы. Целью данного исследования было сформировать актуальное представление о нестероидных противовоспалительных препаратах в медикаментозном сопровождении периоперационного периода хирургии катаракты. Исследование проведено в формате повествовательного обзора. Разнообразие топических нестероидных противовоспалительных препаратов, используемых в офтальмологии, представлено диклофенаком, кеторолаком, бромфенаком, индометацином и непафенаком. Отличия в химической структуре препаратов обусловливают особенности их фармакодинамики и фармакокинетики. В литературе накопилась большая доказательная база в виде результатов рандомизированных исследований с контрольной группой и экспериментальных работ, свидетельствующих о положительных противовоспалительных свойствах нестероидных противовоспалительных препаратов, применяемых в периоперационном периоде хирургии катаракты.</p></sec><sec><title>Заключение</title><p>Заключение. Представленные исследования демонстрируют, что непафенак проявляет выразительные фармакодинамические свойства по проникновению в переднюю камеру глаза, а также оказывает противовоспалительный эффект в заднем сегменте глаза на фоне местного применения, что обусловливает широкий терапевтический потенциал Апфекто. Апфекто – доступный генерический непафенак, произведенный по международным стандартам качества.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>Background</title><p>Background. Medication support of cataract surgery is an integral part of it. The standard regimen of local therapy includes an antibiotic, a glucocorticosteroid, and a nonsteroidal anti-inflammatory drug. Each of the many nonsteroidal anti-inflammatory drugs has unique pharmacological properties, which determines the relevance of information on the choice of a drug from this group in the drug support of cataract surgery.</p></sec><sec><title>Objective</title><p>Objective. The purpose of this study is to form an up-to-date understanding of nonsteroidal anti-inflammatory drugs in the drug support of the perioperative period of cataract surgery. The study was conducted in the format of a narrative review. The variety of topical nonsteroidal anti-inflammatory drugs used in ophthalmology is represented by diclofenac, ketorolac, bromfenac, indomethacin, and nepafenac. Differences in the chemical structure of the drugs determine the features of their pharmacodynamics and pharmacokinetics. A significant amount of evidence has accumulated in the literature in the form of results of randomized studies with a control group and experimental works indicating positive anti-inflammatory properties of nonsteroidal anti-inflammatory drugs used in the perioperative period of cataract surgery.</p></sec><sec><title>Conclusion</title><p>Conclusion. The presented studies demonstrate that nepafenac exhibits significant pharmacodynamic properties for penetration into the anterior chamber of the eye, and also has an anti-inflammatory effect in the posterior segment of the eye against the background of local application, which determines the unique therapeutic potential of Apfecto. Apfecto is a cost-effective generic nepafenac produced with international quality standards.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>катаракта</kwd><kwd>хирургическое лечение</kwd><kwd>нестероидные противовоспалительные препараты</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cataract</kwd><kwd>surgical treatment</kwd><kwd>nonsteroidal anti-inflammatory drugs</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Malyugin B. E., Shpak A. A., Morozova T. A. Pharmacologic support of modern cataract surgery. 27 p. (In Russ.)</mixed-citation><mixed-citation xml:lang="en">Malyugin B. E., Shpak A. A., Morozova T. A. Pharmacologic support of modern cataract surgery. 27 p. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Stein J. D. Serious adverse events after cataract surgery. Curr. Opin. Ophthalmol. 2012; 23 (3): 219-225.</mixed-citation><mixed-citation xml:lang="en">Stein J. D. Serious adverse events after cataract surgery. Curr. Opin. Ophthalmol. 2012; 23 (3): 219-225.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Gaskin G. L., et al. Predictive Modeling of Risk Factors and Complications of Cataract Surgery. Eur. J. Ophthalmol. 2016; 26 (4): 328-337.</mixed-citation><mixed-citation xml:lang="en">Gaskin G. L., et al. Predictive Modeling of Risk Factors and Complications of Cataract Surgery. Eur. J. Ophthalmol. 2016; 26 (4): 328-337.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Nowak J. Z. Non-steroidal anti-inflammatory drugs (NSAIDs) in ophthalmology: pharmacological and clinical characteristics. Mil. Pharm. Med. 2012; 4: 33-50.</mixed-citation><mixed-citation xml:lang="en">Nowak J. Z. Non-steroidal anti-inflammatory drugs (NSAIDs) in ophthalmology: pharmacological and clinical characteristics. Mil. Pharm. Med. 2012; 4: 33-50.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Hoffman R. S., et al. Cataract surgery and non-steroidal antiinflammatory drugs. J. Cataract Refract. Surg. 2016; 42 (9): 1368-1379.</mixed-citation><mixed-citation xml:lang="en">Hoffman R. S., et al. Cataract surgery and non-steroidal antiinflammatory drugs. J. Cataract Refract. Surg. 2016; 42 (9): 1368-1379.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S. J., Flach A. J., Jampol L. M. Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Surv. Ophthalmol. 2010; 55 (2): 108-133.</mixed-citation><mixed-citation xml:lang="en">Kim S. J., Flach A. J., Jampol L. M. Nonsteroidal Anti-inflammatory Drugs in Ophthalmology. Surv. Ophthalmol. 2010; 55 (2): 108-133.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Hirneiß C., et al. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction. Graefe’s Arch. Clin. Exp. Ophthalmol. 2005; 243 (8): 768-773.</mixed-citation><mixed-citation xml:lang="en">Hirneiß C., et al. Comparison of prednisolone 1%, rimexolone 1% and ketorolac tromethamine 0.5% after cataract extraction. Graefe’s Arch. Clin. Exp. Ophthalmol. 2005; 243 (8): 768-773.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Srinivasan R., Madhavaranga. Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery. J. Cataract Refract. Surg. 2002; 28 (3): 517-520.</mixed-citation><mixed-citation xml:lang="en">Srinivasan R., Madhavaranga. Topical ketorolac tromethamine 0.5% versus diclofenac sodium 0.1% to inhibit miosis during cataract surgery. J. Cataract Refract. Surg. 2002; 28 (3): 517-520.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Малюгин Б. Э., Анисимова Н. С., Соболев Н. П. Особенности диафрагмальной функции радужки при фемтосекундном лазерном сопровождении факоэмульсификации на фоне применения различных нестероидных противовоспалительных средств. Офтальмохирургия. 2018; 1: 6-12.</mixed-citation><mixed-citation xml:lang="en">Malyugin B. E., Anisimova N. S., Sobolev N. P. Features of diaphragmatic iris function at femtosecond laser support of phacoemulsification against the background of application of various non-steroidal anti-inflammatory agents. Oftalmokhirurgiya. 2018; 1: 6-12. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S. J., et al. Topical Nonsteroidal Antiinflammatory Drugs and Cataract Surgery. Ophthalmology. 2015; 122 (11): 2159-2168.</mixed-citation><mixed-citation xml:lang="en">Kim S. J., et al. Topical Nonsteroidal Antiinflammatory Drugs and Cataract Surgery. Ophthalmology. 2015; 122 (11): 2159-2168.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Иошин И. Э., Толчинская А. И., Оздербаева А. А. Особенности применения нестероидных противовоспалительных средств (НПВС) в профилактике отека сетчатки макулярной области после факоэмульсификации возрастной катаракты. Российский офтальмологический журнал. 2016; 9 (2): 77-82.</mixed-citation><mixed-citation xml:lang="en">Ioshin I. E., Tolchinskaya A. I., Ozderbaeva A. A. Features of the use of nonsteroidal anti-inflammatory drugs (NSAIDs) in the prevention of macular retinal edema after phacoemulsification of age-related cataract. Rossiiskii oftalmologicheskii zhurnal. 2016; 9 (2): 77-82. (In Russ.)</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Almeida D. R. P., et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. J. Cataract Refract. Surg. 2012; 38 (9): 1537-1543.</mixed-citation><mixed-citation xml:lang="en">Almeida D. R. P., et al. Prophylactic nepafenac and ketorolac versus placebo in preventing postoperative macular edema after uneventful phacoemulsification. J. Cataract Refract. Surg. 2012; 38 (9): 1537-1543.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Costagliola C., et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp. Eye Res. 2005; 81 (5): 610-615.</mixed-citation><mixed-citation xml:lang="en">Costagliola C., et al. The influence of diclofenac ophthalmic solution on the intraocular pressure-lowering effect of topical 0.5% timolol and 0.005% latanoprost in primary open-angle glaucoma patients. Exp. Eye Res. 2005; 81 (5): 610-615.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Lindstrom R., Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr. Med. Res. Opin. 2006; 22 (2): 397-404.</mixed-citation><mixed-citation xml:lang="en">Lindstrom R., Kim T. Ocular permeation and inhibition of retinal inflammation: an examination of data and expert opinion on the clinical utility of nepafenac. Curr. Med. Res. Opin. 2006; 22 (2): 397-404.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Gamache D. A., Graff G., Brady M. T. Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy. Inflammation. 2000; 24: 357-370.</mixed-citation><mixed-citation xml:lang="en">Gamache D. A., Graff G., Brady M. T. Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: I. Assessment of Anti-Inflammatory Efficacy. Inflammation. 2000; 24: 357-370.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Kapin M. A., et al. Inflammation-Mediated Retinal Edema in the Rabbit Is Inhibited by Topical Nepafenac. Inflammation. 2003; 27: 281-291.</mixed-citation><mixed-citation xml:lang="en">Kapin M. A., et al. Inflammation-Mediated Retinal Edema in the Rabbit Is Inhibited by Topical Nepafenac. Inflammation. 2003; 27: 281-291.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Lane S. S., et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J. Cataract Refract. Surg. 2007; 1 (33): 53-58.</mixed-citation><mixed-citation xml:lang="en">Lane S. S., et al. Nepafenac ophthalmic suspension 0.1% for the prevention and treatment of ocular inflammation associated with cataract surgery. J. Cataract Refract. Surg. 2007; 1 (33): 53-58.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
